On February 2, 2023 BriSTAR Immunotech, a clinical-stage cell therapy company, reported that its Chief Executive Officer, James Pan, Ph.D., will be presenting at the 25th BIO CEO & Investor Conference (Press release, Bristar Immunotech, FEB 2, 2023, View Source;investor-conference-301737314.html [SID1234626800]). The conference will take place at the New York Marriott Marquis during February 6-9, 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Pan’s presentation will focus on how BriSTAR’s STAR-T platform is used to formulate novel cell therapy candidates that better address the challenges in treating solid tumors. These challenges include overcoming tumor heterogeneity, antigen escape, tumor infiltration, and the immunosuppressive microenvironment.

Dr. Pan will also discuss the latest developments for the Company’s novel T cell immunotherapy candidates, including lead candidates CD19/CD20 STAR-T and LILRB4 STAR-T. CD19/CD20 STAR-T is currently in clinical trials targeting relapsed/refractory B-cell non-Hodgkin lymphoma and LILRB4 STAR-T is indicated for acute myeloid leukemia (AML).

Details of Dr. Pan’s Presentation are as follows:

Date and Time: February 7, 2023 from 1:45 PM – 2:00 PM (EST)

Location: Winter Garden Room, 6th floor, New York Marriott Marquis

Please visit the website of BIO for more information.